| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002282 | American Journal of Ophthalmology | 2013 | 48 Pages |
Abstract
Therapies based on pathophysiologic features have changed the paradigm for treating neovascular AMD. With improved understanding of the underlying genetic susceptibility, we can identify targets to halt early disease and to prevent progression and vision loss.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Joan W. Miller,